An observational study in Amyotrophic Lateral Sclerosis (ALS) and Motor Neurone Disease (MND), sponsored by Guy's and St Thomas' NHS Foundation Trust. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Guy's and St Thomas' NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom — 15 open to participants now, 22 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · United Kingdom.
Among the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, this one is the 15th largest by planned enrollment of the 15 observational ones that give a count, is one of 7 that started in 2026, is one of 15 observational ones, reaches primary completion later than 19 of the 21 other live ones, and was the 68th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →15 of the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom are open now. Recruiting first, the newest first:
The Leeds Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
Trace Neuroscience, Inc. · Sites in United Kingdom, Germany, Netherlands
Ages 18–75
NHS Greater Glasgow and Clyde · Sites in United Kingdom
Ages 18+
Royal Brompton & Harefield NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Prilenia · Sites in United Kingdom, United States, Belgium and 10 more countries
Ages 18–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 25
First in 2003; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 108 across 266 observational studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 227 across the 55 interventional studies, 73 across the 15 observational. Of the 45 that completed or were terminated, 21 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 70 have an industry lead sponsor. The 10 most frequent:
Guy's and St Thomas' NHS Foundation Trust is the lead sponsor of 295 studies on the registry; 80 are open to participants now.
Guy's and St Thomas' NHS Foundation Trust has 2 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07818772NHS Greater Glasgow and Clyde7T Imaging Pilot-study in Patients With Motor Neuron Disease to Find Non-Invasive Disease Imaging Biomarkers | 2026-11-30 |
| NCT07393932University of SheffieldMND Together: Phase 1 | 2026-12 |
| NCT07943442The Leeds Teaching Hospitals NHS TrustNovel MRI for an Earlier Diagnosis of Motor Neurone Disease | 2027-05-31 |
| NCT07674667Trace Neuroscience, Inc.FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Motor neurone disease (MND) is a progressive neurological condition that can affect movement, speech, swallowing and breathing. Weight loss and malnutrition are common in people with MND and may be caused by factors including swallowing difficulties, reduced food intake, fatigue, breathlessness, loss of muscle mass and changes in the amount of energy the body uses at rest.
Resting energy expenditure can be measured using indirect calorimetry. However, there is limited evidence about whether comprehensive metabolic, nutritional and body composition assessments can be completed acceptably and practically by people with MND during routine clinical appointments.
MET-MND is a single-centre observational feasibility study involving approximately 12-15 adults with MND referred to a specialist respiratory service. Participants will complete one study visit aligned with a routine clinic appointment, followed by a 7-day food diary at home.
The study will evaluate the acceptability, tolerability, practicality, completion and data completeness of metabolic, nutritional and body composition assessments. Findings will be used to refine study procedures and inform the design of future research investigating metabolism and nutrition in people with MND.
MET-MND is a single-centre observational feasibility study conducted within Lane Fox Respiratory Services at Guy's and St Thomas' NHS Foundation Trust. The study will assess the feasibility, acceptability, tolerability and data completeness of collecting metabolic, nutritional and body composition measurements in adults with motor neurone disease during the routine respiratory clinic pathway.
Approximately 12-15 participants will complete one study visit aligned with a routine clinic appointment. The study visit is expected to take approximately 1-1.5 hours. Participants will subsequently complete a 7-day food diary at home.
Metabolic rate will be measured using indirect calorimetry with the Q-NRG+ indirect calorimeter. The assessment will be performed while the participant is resting, using either a ventilated canopy hood or mask according to participant comfort and clinical suitability. The study will assess whether indirect calorimetry can be completed successfully and whether the hood or mask is more suitable for people with MND.
Nutritional assessment will include weight, height, body mass index, percentage weight loss and Subjective Global Assessment. Body composition will be assessed using bioelectrical impedance analysis and skinfold measurements. Participants will also complete the ALS Functional Rating Scale-Revised to record how MND affects day-to-day function.
Participants will be asked to record their food and drink intake for seven consecutive days using the Nutritics Libro app or a paper food diary. The diary will be analysed to estimate energy and protein intake. Assistance with completing the diary may be provided when required.
Participants will be asked a small number of questions about the acceptability of undergoing a Dual-Energy X-ray Absorptiometry scan in future research. No DEXA scan will be performed as part of this feasibility study.
Study feasibility will be evaluated using assessment completion, data completeness, time required, participant acceptability and tolerability, and practical or operational barriers encountered during delivery. Reasons for incomplete assessments, such as fatigue, breathlessness, positioning difficulties or equipment limitations, will be recorded.
Measurements will follow written study procedures. Operator-dependent measurements, including skinfold measurements, will be performed in duplicate or triplicate as specified in the protocol. Analyses will be descriptive and will summarise feasibility measures using frequencies, percentages, means with standard deviations, or medians with interquartile ranges, as appropriate. Reasons for non-completion and barriers to delivery will be summarised narratively.
Findings will be used to refine and optimise the assessment procedures, evaluate participant burden and inform the design of future observational research investigating metabolism and nutrition in MND.
Hospital outpatient department
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Percentage of planned metabolic, nutritional and body composition assessments completed
For each participant, completion status will be recorded for the following planned assessments: indirect calorimetry, Subjective Global Assessment, weight and height measurements, bioelectrical impedance analysis, skinfold measurements, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, DEXA acceptability questions and the 7-day food diary. The number and percentage of participants completing each assessment will be reported separately. Reasons for non-completion will also be recorded.
Time frame: From Day 1 through Day 8. Day 1: single study visit. Days 2-8: seven days following the visit for diary completion
Percentage of Required Data Fields Completed for Each Planned Study Assessment
Data completeness will be assessed separately for indirect calorimetry, Subjective Global Assessment, anthropometry, bioelectrical impedance analysis, skinfold measurements, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, DEXA acceptability questions and the 7-day food diary. The percentage of completed data fields will be reported for each assessment. Reasons for missing data will be recorded.
Time frame: From Day 1 through Day 8.
Participant acceptability and tolerability: number of participants unable to complete each assessment due to acceptability or tolerability of study assessments
Participant acceptability and tolerability will be assessed for the metabolic, nutritional and body composition procedures. The number and percentage of participants who complete, stop, decline or require adaptation of each assessment will be summarised. Recorded reasons may include discomfort, fatigue, breathlessness, claustrophobia, positioning difficulty or other participant-reported or clinical factors.
Time frame: From Day 1 through Day 8
Time taken to complete each in clinic study assessment
The time taken to complete each metabolic, nutritional and body composition assessment will be recorded in minutes: will include indirect calorimetry, Subjective Global Assessment, anthropometry, bioelectrical impedance analysis, skinfold measurements, the ALS Functional Rating Scale-Revised and the DEXA acceptability questions.
Time frame: Day 1
Practicality of integrating assessments into the routine respiratory clinic pathway: percentage completing all in-clinic assessments during one routine clinic visit
The number and percentage of participants for whom all planned in-clinic assessments are completed within the single routine clinic visit will be reported. Operational factors affecting delivery, including room availability, equipment availability, workflow, participant positioning and need for breaks or adaptations, will be recorded and summarised descriptively.
Time frame: Day 1
Completion of Indirect Calorimetry using a canopy hood or mask
The number and percentage of participants who complete indirect calorimetry will be reported by measurement method: ventilated canopy hood or mask. Any need to stop or adapt the procedure and the reasons for non-completion will be recorded.
Time frame: Day 1
Number of Days Completed in the 7-Day Food Diary
The number of diary days completed by each participant using the Nutritics Libro app or paper diary will be recorded, with a possible range of 0-7 days. The number and percentage of participants completing all seven days will also be reported. The availability of information required to estimate energy and protein intake, support required and reasons for incomplete diary data will be summarised.
Time frame: Day 2-8
Participant Responses to the DEXA Acceptability Questions
Responses to the study-specific DEXA acceptability questions will be summarised using the response options specified in the questionnaire. The questions assess whether participants might consider undergoing a DEXA scan in future research and identify practical concerns that could affect acceptability. No DEXA scan will be performed in this study.
Time frame: Day 1
Plan to share: No
Start is estimated for Oct 2026; primary completion for Dec 2029, 38 months later.
Of 129 non-industry observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 125. This study's planned 38 months is below that.
Counting every sponsor, half of 138 studies reached it within 64 months; a quarter within 29 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Guy's and St Thomas' NHS Foundation Trust →